linjc16/ctgov huggingface dataset:
Diagnostic Protocol Of Painful Hip

Study Overview
=================
Brief Summary
-----------------
Nondisplaced hip fractures may be radiographically occult and require MRI or single photon emission CT bone scintigraphy for accurate diagnosis. Both examinations are expensive and are not readily available in many hospitals. Ultrasound (US) examination is relatively inexpensive and preliminary data had demonstrated its efficacy in detecting occult fractures in other sites. Our objective is to evaluate US examination as a screening tool for occult hip fractures in posttraumatic painful hips in the elderly.

Conditions
-----------------
Hip Fracture

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Men and women above 40 years old Trauma to the hip . Extreme difficulty in walking or inability to step on the leg, following sensitivity in the hip joint area after local pressure or in a movement. X ray of the pelvis aimed to the suspected hip joint (including AP lateral position and internal rotation) does not demonstrate fracture in the joint or the pelvis. Exclusion Criteria: 1. None

Ages Eligible for Study
-----------------
Minimum Age: 40 Years
Maximum Age: 85 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Meshed Vein Graft Patency Trial - VEST

Study Overview
=================
Brief Summary
-----------------
The study hypothesis is that a meshed conduit made of safen vein allows a better patency at mid-long term than a safen vein alone. To test this hypothesis the investigators plan a prospective, randomized study, comparing grafts to the diagonal, in cases of vessel diameter under 1.5mm. A control angiography will be performed one year after the operation.

Official Title
-----------------
External Mesh of Vein Grafts In Coronary Artery Bypass Grating: Early Patency and Clinical Outcome

Conditions
-----------------
Coronary Artery Disease

Intervention / Treatment
-----------------
* Device: External Mesh for vein grafts


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Clinical Indication for elective Coronary Artery Bypass Grafting with at least one vein graft Coronary artery with critical stenosis (over 70%) Exclusion Criteria: -
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: External Mesh<br> | Device: External Mesh for vein grafts<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Patency | Patency of graft at CT Scan | 6 to 12 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Major Adverse Cardiac and Cerebrovascular Events (MACCE) |  | 60 months | 
| Vein graft lumen uniformity |  | 6 to 12 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Mesh, Graft, Patency
VTE and the Related Factors Associated With Higher Rates of PE After a DVT in Southwestern China

Study Overview
=================
Brief Summary
-----------------
Little is known about the current management status of venous thromboembolism (VTE) in Southwestern China. We aimed to investigate the status of anticoagulant administration in VTE in Southwestern China and assess the potential predictors of deep vein thrombosis (DVT) complicated pulmonary embolism (PE). We extracted data from YiduCloud database from December 2006 to November 2018 and performed a cross-sectional survey of VTE. The demographics, laboratory tests, and anticoagulants were collected and analyzed in the logistic regression model, classification tree and Random Forest model.

Detailed Description
-----------------
We established a collaborative epidemiological work of southwestern China for our cross-sectional survey sample, which included hospitalized patients in the seven main medical centers who met the inclusion criteria. The Human Research Committee of Chongqing Medical University approved this study and waived the need for informed consent. Patients were eligible to be included in the study if they are admitted or discharged with a diagnosis of DVT or/and PE and if they ever received treatment in the seven medical centers between December 2006 to November 2018.

Official Title
-----------------
The Real-World Treatment Status of Venous Thromboembolism and the Related Factors Associated With Higher Rates of PE After a DVT in Southwestern China

Conditions
-----------------
Venous Thromboembolism; Deep Vein Thrombosis; Pulmonary Embolism; Anticoagulants

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: - In the Chinese VTE guidelines, the diagnosis of VTE depends on a series of tests. D-dimer was used to screen for thrombosis, and limb venous ultrasound was used to diagnose DVT. CT pulmonary angiography (CTPA) or pulmonary ventilation perfusion scan was used for the diagnosis of pulmonary embolism. Through the retrieval of patient diagnosis in the database, we retrieved the basic data of all patients diagnosed as VTE during the study period. Exclusion Criteria: -
Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The maternal cardiac events and the neonatal complications | Primary outcomes of interest were major adverse cardiac events (MACEs), obstetric complications and neonatal adverse clinical events (NACEs). | 2010-2019 |
Biological Evaluation of a Novel Anti-inflammatory Treatment in Immune-mediated Inflammatory Diseases

Study Overview
=================
Brief Summary
-----------------
The aim of the study is to investigate in vitro the impact of a novel anti-inflammatory treatment on costimulatory molecules expressed on monocytes.

Official Title
-----------------
Biological Evaluation of a Novel Anti-inflammatory Treatment in Immune-mediated Inflammatory Diseases

Conditions
-----------------
Inflammation

Intervention / Treatment
-----------------
* Biological: Blood sample


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Immune-mediated inflammatory disease (non-ST segment elevation myocardial infarction, Rheumatoid arthritis, Chronic obstructive pulmonary disease, Idiopathic pulmonary fibrosis, Crohn's disease, Ulcerative colitis, Cystic fibrosis, Psoriasis, Multiple sclerosis or major depressive episode) Patient able to understand the reason of the study Patient not opposed to the conservation of biological samples for scientific research Exclusion Criteria: Pregnant woman Subject without health insurance

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 85 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Immune-mediated inflammatory disease<br>Patients with an immune-mediated inflammatory disease. A blood sample is achieved at T0 (no follow-up). | Biological: Blood sample<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Expression of costimulatory molecules CD86, CD80, CD40 and class II (HLA-DR) on monocytes |  | 24 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Immunomodulation
Larsen & Toubro (L&T) Noninvasive Blood Pressure Module Performance Validation

Study Overview
=================
Brief Summary
-----------------
To validate accuracy of the readings of noninvasive blood pressure (NIBP) module with sphygmomanometer as per the requirements of AAMI SP10:2002. This study is for adult and pediatric population.

Official Title
-----------------
L&T Noninvasive Blood Pressure Module Performance Validation

Conditions
-----------------
Blood Pressure

Participation Criteria
=================
Eligibility Criteria
-----------------
Subjects: Healthy volunteers Inclusion Criteria: Healthy subjects Age between 1 - 60 yrs Both genders Consenting for the study Exclusion Criteria: Subjects suffering from cardiorespiratory, neurological or endocrinal disorders Subjects with alcohol abuse/dependance Female subjects who are pregnant or lactating Subjects with pace maker implantations Subjects: Diseased subjects Inclusion Criteria: Patients of hypertensive, ICU and in patients of different diseases Age between 1 - 80 yrs Both genders Consenting for the study Exclusion Criteria: Healthy volunteers

Ages Eligible for Study
-----------------
Minimum Age: 1 Year
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Non-Invasive Blood Pressure
Control of Myopia Using Novel Spectacle Lens Designs

Study Overview
=================
Brief Summary
-----------------
Randomized, controlled, multisite, subject-and observer-masked, 3-arm parallel group clinical trial of 36-month duration to evaluate the safety and efficacy of a novel spectacle lens design in reducing the progression of juvenile myopia.

Official Title
-----------------
Efficacy and Safety Study of Novel Spectacle Lens Designs to Control of Myopia

Conditions
-----------------
Juvenile Myopia

Intervention / Treatment
-----------------
* Device: Novel spectacle lens design
* Device: Spectacle lenses


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Children 6-10 years of age (day prior to 10th birthday) at time of informed consent/assent SER error between -0.75 and -4.50 D SER power between the two eyes must be less than or equal to 1.50 D Willingness to participate in the trial for 3 years without content lens wear Exclusion Criteria: Previous or current use of contact lenses Previous or current use of bifocals, progressive addition spectacles lenses Previous or current use of myopia control treatment Astigmatism worse then -1.25 DC in either eye

Ages Eligible for Study
-----------------
Minimum Age: 6 Years
Maximum Age: 10 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Test Arm 1<br>Single vision, impact-resistant spectacle lenses | Device: Novel spectacle lens design<br>* Use of lenses may reduce the rate of progression of juvenile myopia<br>|
| Experimental: Test Arm 2<br>Single vision, impact-resistant spectacle lenses | Device: Novel spectacle lens design<br>* Use of lenses may reduce the rate of progression of juvenile myopia<br>|
| Other: Test Arm 3<br>Single vision, impact-resistant spectacle lenses | Device: Spectacle lenses<br>* Use of lenses may reduce the rate of progression of juvenile myopia<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Axial length | Change in axial length from baseline | 36 Months | 
| Spherical equivalent refraction | Change in spherical equivalent refraction from baseline | 36 Months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Myopia
A Real-world Study for Patients With Multiple Pulmonary Ground-glass Nodules

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to actively monitor patients with multiple pulmonary Ground-glass Nodules (GGNs), in order to provide evidence for multiple GGNs treatment.

Detailed Description
-----------------
Multiple pulmonary GGNs are very commonly identified particularly as increasing numbers of CT scans are performed as part of routine lung cancer screening. At the same time, the ideal solution for these cases continues to be debated. This aim of this study is to learn more about the effects of multiple factors on outcome of multiple pulmonary GGNs, such as patients' clinical characteristics, CT features and different pathological types. Furthermore, the optimal timing of surgery and the effect of different surgical choices on the prognosis of patients with multiple GGNs will be investigated.

Official Title
-----------------
A Real-world Study for Patients With Multiple Pulmonary Ground-glass Nodules

Conditions
-----------------
Multiple Pulmonary Nodules

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age greater than 18 years Have two or more GGNs on CT imaging Diameter of GGNs > 5mm and ≤ 3cm GGNs must be greater than half ground glass Exclusion Criteria: patients who have a history of lung cancer patients who have undergone chemotherapy, radiotherapy or targeted therapy before surgery pregnant women

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| 5-year overall survival [Time Frame: From date of the recruitment, assessed up to 60 months] | 5-year overall survival | October 31, 2024 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| 5-year Progression-Free-Survival [Time Frame: From date of the recruitment, assessed up to 60 months] | 5-year Progression-Free-Survival | October 31, 2024 | 
| Recurrence-free survival [Time Frame: From date of the recruitment, assessed up to 60 months] | Recurrence-free survival | October 31, 2024 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Lung Neoplasms, Multiple Pulmonary Nodules
Venous Congestion and Acute Renal Failure in Cardiac Surgery Postoperative

Study Overview
=================
Brief Summary
-----------------
Acute renal failure (ARF) is a frequent complication in the postoperative cardiac surgery, and is a major risk factor for mortality in this context. The right ventricular dysfunction post cardiopulmonary bypass (CPB) is also a common complication, close to 100% if one takes into account the transient dysfunction. A recent study showed that right ventricular dysfunction and the IRA seemed related, rather on the slope of venous congestion. We wish to study this phenomenon more specifically in particular to offer reliable diagnostic markers of venous congestion.

Official Title
-----------------
Venous Congestion and Acute Renal Failure in Cardiac Surgery Postoperative (COVD)

Conditions
-----------------
Acute Renal Failure (ARF)

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age: all major patient Gender: both Subject has signed an informed consent IRA KDIGO stage 1 or urine output <0.5 mL / kg / h for at least 6 hours / elevation creat> 26.5μmol / L Patient in sinus rhythm at the time of the ultrasound measurements No diuretic since intervention Absence of circulatory failure (low doses of catecholamines tolerated) Extubated: absence of mechanical ventilation Exclusion Criteria: Chronic heart failure right Chronic renal failure (GFR <60) Usual treatment with high dose diuretics (furosemide> 40mg / day) Endocarditis Emergency surgery (aortic dissection, emergency bypass surgery) / heart surgery D / redux Circulatory Support ACFA / electro-paced rhythm Inability to give informed about information (subject in emergencies, understanding of the subject of difficulty, ...) Topic under judicial protection Topic guardianship or curatorship Pregnancy (women of childbearing age) Breastfeeding

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Quantification of sonographic markers of right ventricular |  | 1 hour after cardiac surgery | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Renal Failure, Renal Insufficiency, Acute Renal Failure, Acute Renal Injury, Kidney Failure, Kidney Insufficiency, Acute Kidney Failure, Acute Kidney Injury, Ventricular dysfunction, Venous congestion, Renal function, Kidney function, Venous heart failure
Metformin in Children With Motor Deficit

Study Overview
=================
Brief Summary
-----------------
Obesity with insulin resistance in the paediatric population provides an increasing challenge. Children with neurological or neuromuscular diseases are even more prone to obesity: their locomotor impairment leads to an increasingly sedentary lifestyle, a decrease in physical fitness and an increase in body fat (1-3). Obesity, in turn, can be associated with a decrease in physical fitness and a further increase in body fat. In this study we want to evaluate the effect of an insulin-sensitizer, metformin, in a group of overweight/obese patients with neurological or neuromuscular diseases. Metformin is a well-established insulin sensitizer.

Official Title
-----------------
Metformin in Children With Motor Deficit

Conditions
-----------------
Spina Bifida, Neuromuscular Diseases

Intervention / Treatment
-----------------
* Drug: Metformin
* Drug: placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with neurogenic or myogenic motor deficit, clinically obese or who had excessively gained weight over the last year. Exclusion Criteria: Exclusion criteria were known type 1 or type 2 diabetes mellitus and contraindications to metformin therapy.

Ages Eligible for Study
-----------------
Minimum Age: 8 Years
Maximum Age: 35 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: A<br>Metformin during 12 months and then 6 months Placebo | Drug: Metformin<br>* daily 850 mg<br>Drug: placebo<br>* placebo<br>|
| Placebo Comparator: B<br>Placebo during 6 months, afterwards 12 months metformin | Drug: Metformin<br>* daily 850 mg<br>Drug: placebo<br>* placebo<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| insulin resistance |  | 18 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| fat |  | 18 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
metformin, spina bifida, duchenne, insulin resistance
An Observational Clinical Study to Evaluate COVID-19 Symptoms in Long Hauler Patients Who Participated in K031-120 or K032-120

Study Overview
=================
Brief Summary
-----------------
This observational clinical study aims to evaluate the presence of symptoms of COVID-19 infection in patients who participated in K031-120 or K032-120 (long hauler).

Official Title
-----------------
An Observational Study to Evaluate the Presence of Symptoms After COVID-19 Infection in Patients Who Participated in K031-120 or K032-120 Study (Long Hauler)

Conditions
-----------------
COVID-19

Intervention / Treatment
-----------------
* Other: KB109 + Self Supportive Care
* Other: Self Supportive Care (SSC) Alone


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Have consented to participate over the telephone Have been randomized in either the K031-120 or K032-120 study Exclusion Criteria: Have withdrawn consent from K031-120 or K032-120

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| KB109 + Self Supportive Care (SSC)<br> | Other: KB109 + Self Supportive Care<br>* KB109 is a novel glycan<br>|
| Self Supportive Care (SSC) Alone<br> | Other: Self Supportive Care (SSC) Alone<br>* Self Supportive Care (SSC) Alone<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Proportion of patients with persistent COVID-19 symptoms for at least 12-weeks post-randomization in K031-120 or K032-120 study. |  | 12-weeks from randomization in K031-120 or K032-120 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
K031-120, MMT, Microbiome, COVID-19, Corona Virus, Corona Virus Disease, Kaleido, Kaleido Biosciences, KB109, Oligosaccharide, Glycan, Microbiome metabolic therapy, Supportive Self Care, SSC, Telemedicine, K032-120